Literature DB >> 3821940

Absorption, metabolism and elimination of strophanthus glycosides in man.

H Strobach, K E Wirth, K Rojsathaporn.   

Abstract

In 33 healthy male volunteers, given a single oral and intravenous dose of cymarin (k-strophanthin-alpha), k-strophanthoside (k-strophanthin-gamma) and ouabain (g-strophanthin), enteral absorption and renal excretion of these glycosides and their metabolites were investigated by radioimmunoassay and HPLC. Cymarin was absorbed at 47% of the given dose. After intravenous injection 46% and after oral administration 21% of the given dose, i.e. the total amount as detected by radioimmunoassay which consisted of the unchanged glycoside and its metabolites, were excreted by the kidneys mainly as conjugated metabolites. The half-life of elimination, calculated from the total excreted amount was 13 h (i.v.) and 23 h (p.o.), respectively. k-Strophanthoside was absorbed at 16% of the given dose. After i.v.-injection 73% of the given dose was excreted by the kidneys with a half-life of elimination of 99 h. From this total amount about 70% was excreted as the unchanged drug, the remaining 30% as various metabolites. After oral administration 11% of the given dose were excreted with a half-life of elimination of 22 h. 80% of this amount consisted mainly of conjugated k-strophanthoside and conjugated metabolites as k-strophanthin-beta, cymarin, k-strophanthidin, cymarol and k-strophanthidol. Only 6% was excreted as the unchanged drug. Ouabain was absorbed after oral administration to a minimum of 1.4%. Given intravenously a total renal excretion of 33% of the given dose with a half-life of elimination of 23 h was measured. Of this 80% was unchanged ouabain.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3821940     DOI: 10.1007/bf00569392

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  12 in total

1.  [THE REDUCTION OF THE ALDEHYDE GROUP OF STROPHANTHIDIN AND ITS GLYCOSIDES IN ANIMAL METABOLISM].

Authors:  F LAUTERBACH
Journal:  Naunyn Schmiedebergs Arch Exp Pathol Pharmakol       Date:  1964-04-09

2.  DISTRIBUTION IN PLASMA, UPTAKE BY THE HEART AND EXCRETION OF OUABAIN-H3 IN HUMAN SUBJECTS.

Authors:  B H MARKS; S DUTTA; J GAUTHIER; D ELLIOTT
Journal:  J Pharmacol Exp Ther       Date:  1964-09       Impact factor: 4.030

3.  [Cleavage of cardiac glycosides in the animal body].

Authors:  R ENGLER; P HOLTZ; H W RAUDONAT
Journal:  Naunyn Schmiedebergs Arch Exp Pathol Pharmakol       Date:  1958

4.  [Pharmacokinetics of g-strophanthin].

Authors:  K Greeff; E Köhler; H Strobach; E Verspohl
Journal:  Verh Dtsch Ges Kreislaufforsch       Date:  1974

5.  Renal and gastrointestinal excretion of ouabain in dog and man.

Authors:  R Selden; M N Margolies; T W Smith
Journal:  J Pharmacol Exp Ther       Date:  1974-03       Impact factor: 4.030

6.  Plasma levels and urinary excretion of K-strophanthoside (3H) administered rectally to human subjects.

Authors:  P Ghirardi; A Marzo; M Gianfranceschi; L Bertoli; F Conti; O Mantero
Journal:  Arzneimittelforschung       Date:  1973-11

7.  [Comulative behavior of various cardiac glycosides in anuria].

Authors:  P Kramer; J Horenkamp; B Willms; F Scheler
Journal:  Dtsch Med Wochenschr       Date:  1970-02-27       Impact factor: 0.628

8.  [On the blood level and secretion of radioactively labeled cardiac glycosides following intraduodenal application in the cat].

Authors:  H Lahrtz; R W Sattler; P A van Zwieten
Journal:  Z Gesamte Exp Med       Date:  1968

9.  [Influence of liver and kidney diseases on the serum level and urinary excretion of 3H-g-strophanthin].

Authors:  H Lahrtz; P A van Zwieten
Journal:  Naunyn Schmiedebergs Arch Exp Pathol Pharmakol       Date:  1968

10.  [The enzymatic decomposition of D-digitoxose, D-cymarose and L-thevetose from cardiac glycosides by liver sections].

Authors:  F LAUTERBACH; K REPKE; D NITZ
Journal:  Naunyn Schmiedebergs Arch Exp Pathol Pharmakol       Date:  1960
View more
  3 in total

1.  Discovery of novel antifungal (1,3)-beta-D-glucan synthase inhibitors.

Authors:  J Onishi; M Meinz; J Thompson; J Curotto; S Dreikorn; M Rosenbach; C Douglas; G Abruzzo; A Flattery; L Kong; A Cabello; F Vicente; F Pelaez; M T Diez; I Martin; G Bills; R Giacobbe; A Dombrowski; R Schwartz; S Morris; G Harris; A Tsipouras; K Wilson; M B Kurtz
Journal:  Antimicrob Agents Chemother       Date:  2000-02       Impact factor: 5.191

2.  Inhibition of the HIF-1 Survival Pathway as a Strategy to Augment Photodynamic Therapy Efficacy.

Authors:  Mark J de Keijzer; Daniel J de Klerk; Lianne R de Haan; Robert T van Kooten; Leonardo P Franchi; Lionel M Dias; Tony G Kleijn; Diederick J van Doorn; Michal Heger
Journal:  Methods Mol Biol       Date:  2022

3.  Drug screening and genome editing in human pancreatic cancer organoids identifies drug-gene interactions and candidates for off-label treatment.

Authors:  Christian K Hirt; Tijmen H Booij; Linda Grob; Patrik Simmler; Nora C Toussaint; David Keller; Doreen Taube; Vanessa Ludwig; Alexander Goryachkin; Chantal Pauli; Daniela Lenggenhager; Daniel J Stekhoven; Christian U Stirnimann; Katharina Endhardt; Femke Ringnalda; Lukas Villiger; Alexander Siebenhüner; Sofia Karkampouna; Marta De Menna; Janette Beshay; Hagen Klett; Marianna Kruithof-de Julio; Julia Schüler; Gerald Schwank
Journal:  Cell Genom       Date:  2022-02
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.